Rethinking Medications: From Academic Detailing to Broken Drug Regulation

Jan 25
1 min read

Updated: Jun 29

With Mirko von Hein and The Pharma Perspective.

https://www.youtube.com/watch?v=kNT5gqp9qf4

Harvard professor Jerry Avorn and I discuss drug regulation, FDA approval standards, surrogate endpoints, pharmaceutical pricing, public research funding, medical misinformation, and what all of this means for patients, innovation, and health policy.

Recent Posts

See All

Healing Our De-Commissioned FDA

From HealthAffairs. By Aaron S. Kesselheim and Jerry Avorn. At a time of rapidly developing new medications and growing public health challenges, there is now no official leadership in place at the Fo

The 25th Anniversary of a Nearly Unknown Health Policy Turning Point

From the New England Journal of Medicine. By Jerry Avorn, MD. SUMMARY: In this NEJM Perspective, Dr. Avorn reflects on a physician-designed Massachusetts ballot initiative from the year 2000 that so

Countering the Drug Marketing Machine

Harlan Krumholz & Howard Forman, Yale Medical School | Health & Veritas Podcast. In a Wide-Ranging Interview, Dr. Jerry Avorn Explains How the Drug Marketing Machine Works — and How to Counter It Sour